Exhibit 99.1 IQVIA Reports Third-Quarter 2025 Results RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – October 28, 2025 – IQVIA Holdings Inc. ("IQVIA") (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2025. Third-Quarter 2025 Operating Results Revenue for the third quarter of $4,100 million increased 5.2 percent on a reported ...

Core Insights - IQVIA Holdings Inc. is a global leader in healthcare data, analytics, technology, and clinical research services with a market cap of $34.6 billion [1] - The company operates in three main segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, serving clients in over 100 countries [1] Earnings Expectations - IQV is set to report Q3 earnings on October 28, with analysts expecting a profit of $2.68 per share, a 2.7% increase from $2.61 per share in the same quarter last year [2] - For the current fiscal year, analysts project an EPS of $10.73, reflecting a 4.7% increase from $10.25 in fiscal 2024, with further growth expected to $11.81 by fiscal 2026, a 10.1% annual improvement [3] Stock Performance - Over the past 52 weeks, IQV's stock has declined by 12.2%, underperforming the S&P 500 Index, which rose by 13.4%, and the Health Care Select Sector SPDR Fund, which decreased by 8% [4] Analyst Ratings - Truist Financial analyst Jailendra Singh reaffirmed a "Buy" rating on IQVIA, indicating confidence in the company's growth prospects, which led to a 2.8% increase in share price in the following trading session [5] - The consensus among analysts is highly bullish, with a "Strong Buy" rating from 15 out of 21 analysts, one recommending a "Moderate Buy," and five advising "Hold." The mean price target is $220.45, suggesting a potential upside of 7.7% from the current market price [6]

Upgrades - RBC Capital upgraded Sealed Air (SEE) to Outperform from Sector Perform with a price target of $48, up from $35, citing stabilization in Protective and continued strength in Food segments, along with over $100 million of cost reductions and G&A optimization [2] - Citi upgraded Tractor Supply (TSCO) to Buy from Neutral with a price target of $62, up from $60, noting same-store sales momentum and earnings growth heading into 2026 [2] - Piper Sandler upgraded PNC Financial (PNC) to Overweight from Neutral with a price target of $220, up from $211, expressing confidence in PNC's near-term prospects due to its conservative guidance and attractive valuation [3] - HSBC upgraded Iqvia (IQV) to Buy from Hold with a price target of $235, up from $195, expecting easing regulatory clouds in pharma to support a re-rating of the shares [3] - MoffettNathanson upgraded Roblox (RBLX) to Neutral from Sell, acknowledging that user metrics have significantly improved driven by new viral experiences [4] Downgrades - Jefferies downgraded Freshpet (FRPT) to Hold from Buy with a price target of $53, down from $97, citing an abrupt and persistent growth slowdown and lack of near-term catalysts [5] - HSBC downgraded Bloom Energy (BE) to Hold from Buy with a price target of $100, up from $44, while expecting consensus estimates to revise higher but awaiting a better entry point [5] - RBC Capital downgraded Graphic Packaging (GPK) to Sector Perform from Outperform with a price target of $21, down from $25, due to oversupply in bleached paperboard limiting price increases [5] - JPMorgan downgraded RenaissanceRe (RNR) to Neutral from Overweight with an unchanged price target of $303, adopting an incrementally cautious view on reinsurance pricing [5] - Northland downgraded Nutanix (NTNX) to Market Perform from Outperform with a price target of $76, highlighting risks related to VMware customer migrations and competition from Red Hat [5]

Core Insights - Artisan Partners' "Artisan Select Equity Fund" reported returns of 6.77%, 6.76%, and 6.80% for its Investor Class, Advisor Class, and Institutional Class respectively in Q2 2025, underperforming the S&P 500 Index which returned 10.94% [1] Company Insights - IQVIA Holdings Inc. is highlighted as a key stock in the Artisan Select Equity Fund's portfolio, operating in the analytical technology services and clinical research sector for life sciences and healthcare [2][3] - The stock of IQVIA Holdings Inc. experienced a one-month return of -5.90% and a 52-week decline of 24.23%, closing at $179.56 per share with a market capitalization of $30.525 billion as of September 26, 2025 [2] Industry Insights - The contract research organization (CRO) industry, where IQVIA is a leader, has seen a significant increase in clinical trial outsourcing, with penetration rising from approximately 30% 15 years ago to over 50% currently, with projections suggesting it could reach 70% or more [3] - IQVIA holds a 22% market share in the CRO industry, followed closely by ICON and PPD (a unit of ThermoFisher), each with a 20% share, indicating a fragmented industry landscape [3]

Group 1 - Illumina's stock has dropped by 11% in a week due to increased competition from China's MGI Tech, which is gaining market share in DNA sequencing [2] - MGI Tech's global market presence remains strong despite a recent decline in international sales due to U.S. sanctions [2] - IQVIA presents stronger revenue growth at 5.3% compared to Illumina's decline of 4.8%, indicating a potentially better investment opportunity [3][6] Group 2 - Illumina offers solutions for genomic analysis and sequencing, serving research and clinical markets globally [4] - IQVIA provides advanced analytics and clinical research services, including cloud applications and project management for the life sciences sector [4] - IQVIA's revenue growth for the last 12 months is 3.6%, surpassing Illumina's -3.3%, and IQVIA's average margin is 13.7% compared to Illumina's 6.7% [6]

Group 1: Broyhill Asset Management Performance - Broyhill Partners appreciated 3.7% net of all fees and expenses in Q2 2025, underperforming the MSCI All Country World Index which returned 11.7% [1] - For the six months ended June 30, the strategy returned 6.6% net of all fees and expenses, compared to 10.3% for the index [1] Group 2: IQVIA Holdings Inc. Overview - IQVIA Holdings Inc. (NYSE:IQV) is an analytical technology services and clinical research provider for the life sciences and healthcare industries [2] - The stock experienced a one-month return of -0.50% and a 52-week loss of 21.44%, closing at $190.20 per share with a market capitalization of $32.334 billion on September 18, 2025 [2] Group 3: Investment Insights on IQVIA Holdings Inc. - Broyhill Asset Management added a new position in IQVIA Holdings Inc. following a market dislocation, recognizing its entrenched revenue stream and competitive advantages [3] - IQVIA is a result of the 2016 merger between Quintiles and IMS Health, focusing on later-stage trials and generating significant profits from its technology and data business [3] - Despite its strengths, IQVIA shares are valued at 11x forward earnings, which is below historical levels [3] Group 4: Market Position and Earnings of IQVIA Holdings Inc. - IQVIA Holdings reported record revenue of $4 billion in Q2 2025, but is not among the 30 most popular stocks among hedge funds, with 65 hedge fund portfolios holding the stock at the end of Q2, down from 67 in the previous quarter [4] - While IQVIA is recognized for its potential, certain AI stocks are viewed as offering greater upside potential and less downside risk [4]

Company Overview - IQVIA Holdings Inc. has a market cap of $32.2 billion and is a leading global provider of advanced analytics, technology solutions, and clinical research services for the life sciences industry [1] - The company operates through four segments: Technology & Analytics Solutions, Research & Development Solutions, Contract Sales & Medical Solutions, and Contract Sales & Medical Solutions [1] Market Position and Growth Potential - IQVIA is classified as a "large-cap" stock and is positioned for steady growth due to its diverse offerings and strong backlog, with digital health and AI trends providing long-term tailwinds [2] - The company has a consensus rating of "Strong Buy" from 22 analysts, with a mean price target of $213.52, indicating a potential upside of 16.1% from current market prices [6] Stock Performance - Shares of IQVIA have decreased 25.9% from their 52-week high of $248.03, but have surged 15.1% over the past three months, outperforming the Langar Global Healthtech ETF's (LGHT) 1.3% decrease [3] - Year-to-date, IQVIA's stock has declined 6.4%, lagging behind LGHT's marginal rise, and over the past 52 weeks, shares have plunged nearly 21.8%, compared to LGHT's 2.3% drop [4] Recent Financial Results - On July 22, IQVIA shares jumped 17.9% following the release of Q2 results, with adjusted EPS of $2.81 exceeding Wall Street's estimate of $2.76, and revenue of $4.02 billion surpassing expectations of $3.96 billion [5] - The company guided for full-year adjusted EPS between $11.75 and $12.05 and revenue in the range of $16.1 to $16.3 billion [5] Competitive Landscape - Top rival Agilent Technologies, Inc. has seen its shares fall 7.6% year-to-date and 10.1% over the past 52 weeks, which is a greater decline than IQVIA's performance during the same timeframe [6]

Group 1 - The company IQVIA (NYSE: IQV) is rated with a buy recommendation, indicating a positive outlook for generating value for investors [1] - The analysis suggests that despite regulatory changes, such as the U.S. President signing an executive order affecting drugmakers, the company is expected to perform well [1] Group 2 - The analyst has a background in economics and statistics, with experience in analyzing agricultural commodities and managing trading and data analysis teams [1] - The analyst's approach to generating investment recommendations is based on financial statements, regulations, and macroeconomic variables [1]

Group 1 - IQVIA Holdings Inc. has partnered with Flagship Pioneering to enhance the growth of innovative life sciences companies [2][3] - The collaboration will leverage IQVIA's extensive data assets, AI-driven analytics, and expertise throughout the drug development cycle, aiming to improve the success rate of early-stage therapies [3][4] - Both companies anticipate that this partnership will lead to faster and more efficient drug development, ultimately delivering transformative treatments to patients and creating long-term value in the life sciences sector [4] Group 2 - Despite the potential of IQVIA as an investment, there are other AI stocks that are perceived to offer greater upside potential and lower downside risk [5]

Financial Data and Key Metrics Changes - Total revenue for the quarter was $789 million, with non-GAAP operating income of $353 million, exceeding guidance [7] - The company raised its full-year billings guidance by $35 million, aligning with the revenue increase [16] Business Line Data and Key Metrics Changes - R&D subscriptions and services showed larger upside compared to previous models, indicating strong performance in this segment [20] - Commercial subscriptions remained flat quarter-over-quarter, with Crossix highlighted as a strong performer [72] Market Data and Key Metrics Changes - The resolution of the lawsuit with IQVIA is expected to unlock significant opportunities in the commercial area, enhancing product offerings and customer satisfaction [11][14] - The company has nine top 20 customers committed to Vault CRM, compared to three for Salesforce, indicating a strong competitive position [51] Company Strategy and Development Direction - The company is focusing on Veeva AI as a transformative element for both Veeva and the industry, with plans to monetize AI through industry-specific agents [7][27] - The resolution with IQVIA allows for greater integration of data into Veeva's products, enhancing the overall commercial suite [71] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving the $6 billion revenue target over the next five years, with no material changes expected in the quality segment [22] - The macro environment remains stable, with customers effectively navigating uncertainty and continuing to build pipelines [121] Other Important Information - The company is working on a platform-first approach for horizontal software, with CRM as the first application to be developed [63] - The integration of AI into the Vault platform is expected to create significant value for the industry over time, although material revenue contributions are not anticipated until 2026 or 2027 [29][30] Q&A Session Summary Question: Resolution of the lawsuit with IQVIA - Management noted that the resolution was due to changes in the industry and a mutual understanding that collaboration would benefit customers [11] Question: Confidence in billings guidance - Management indicated that annual billings are a better indicator of performance, and they are pleased with the increase in guidance [16] Question: Evolution of quality cloud - Management confirmed that quality cloud is receiving elevated focus and is expected to be a significant area of growth [20] Question: AI opportunities - Management discussed the potential for AI to enhance productivity and efficiency across various applications, with a focus on deep industry-specific agents [27][46] Question: Customer reaction to IQVIA resolution - Customer feedback has been overwhelmingly positive, with many exploring new possibilities for integration [34] Question: R&D subscription growth - Management attributed the growth to broad-based execution and a stable environment [40] Question: Resistance to change in Compass product suite - Management acknowledged some resistance but expressed confidence in overcoming these challenges as customers adapt [116]